KNSA vs. CRDO
KNSA (Kiniksa Pharmaceuticals, Ltd.) and CRDO (Credo Technology Group Holding Ltd) are both stocks. KNSA operates in Biotechnology (Healthcare), while CRDO operates in Semiconductors (Technology). Over the past 3 years, KNSA returned 57.85%/yr vs 130.87%/yr for CRDO. Their 0.14 correlation means their historical movements had little consistent relationship.
Performance
KNSA vs. CRDO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KNSA achieves a 80.22% return, which is significantly higher than CRDO's 43.85% return.
KNSA
- 1D
- -4.94%
- 1M
- 18.22%
- 6M
- 69.26%
- YTD
- 80.22%
- 1Y
- 145.67%
- 3Y*
- 57.85%
- 5Y*
- 37.13%
- 10Y*
- —
- ALL TIME*
- 14.55%
CRDO
- 1D
- 2.94%
- 1M
- -20.11%
- 6M
- 65.22%
- YTD
- 43.85%
- 1Y
- 85.56%
- 3Y*
- 130.87%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 87.78%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $1.17B | $1.40B | $1.87B | |
| $68.75M | $54.52M | $46.86M |
KNSA vs. CRDO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
KNSA Kiniksa Pharmaceuticals, Ltd. | 80.22% | 108.54% | 12.77% | 17.09% | 34.23% |
CRDO Credo Technology Group Holding Ltd | 43.85% | 114.09% | 245.20% | 46.28% | 10.00% |
Correlation
The correlation between KNSA and CRDO is -0.04, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | -0.04 |
Correlation (3Y) Balances recent behavior with more history. | 0.12 |
Correlation (All Time) Calculated using the full available price history since Jan 27, 2022 | 0.14 |
The correlation between KNSA and CRDO shifts across timeframes, from -0.04 (1 year) to 0.14 (all time), reflecting how their relationship changes across market environments.
Fundamentals
KNSA:
$5.67B
CRDO:
$38.60B
KNSA:
$1.00
CRDO:
$2.50
KNSA:
74.38
CRDO:
82.94
KNSA:
0.72
CRDO:
0.07
KNSA:
7.14
CRDO:
29.34
KNSA:
9.48
CRDO:
19.33
KNSA:
$840.85M
CRDO:
$1.34B
KNSA:
$546.22M
CRDO:
$908.35M
KNSA:
$111.62M
CRDO:
$463.79M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KNSA vs. CRDO — Risk / Return Rank
KNSA
CRDO
KNSA vs. CRDO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and Credo Technology Group Holding Ltd (CRDO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KNSA | CRDO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.01 | ||
| Sortino ratioReturn per unit of downside risk | +2.44 | ||
| Omega ratioGain probability vs. loss probability | 1.52 | 1.20 | +0.32 |
| Calmar ratioReturn relative to maximum drawdown | 6.94 | 1.61 | +5.34 |
| Martin ratioReturn relative to average drawdown | 24.13 | 3.65 | +20.48 |
Loading charts...
Drawdowns
KNSA vs. CRDO - Drawdown Comparison
The maximum KNSA drawdown since its inception was -83.06%, which is greater than CRDO's maximum drawdown of -62.04%. Use the drawdown chart below to compare losses from any high point for KNSA and CRDO.
Loading charts...
Drawdown Indicators
| KNSA | CRDO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.06% | -62.04% | -21.02% |
Max Drawdown (1Y)Largest decline over 1 year | -21.12% | -53.59% | +32.47% |
Max Drawdown (3Y)Largest decline over 3 years | -34.14% | -61.05% | +26.91% |
Max Drawdown (5Y)Largest decline over 5 years | -53.17% | — | — |
Current DrawdownCurrent decline from peak | -8.13% | -31.58% | +23.45% |
Average DrawdownAverage peak-to-trough decline | -40.09% | -19.39% | -20.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.06% | 23.55% | -17.49% |
Volatility
KNSA vs. CRDO - Volatility Comparison
The current volatility for Kiniksa Pharmaceuticals, Ltd. (KNSA) is 26.47%, while Credo Technology Group Holding Ltd (CRDO) has a volatility of 29.83%. This indicates that KNSA experiences smaller price fluctuations and is considered to be less risky than CRDO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KNSA | CRDO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.47% | 29.83% | -3.36% |
Volatility (6M)Calculated over the trailing 6-month period | 41.55% | 73.09% | -31.54% |
Volatility (1Y)Calculated over the trailing 1-year period | 49.77% | 92.00% | -42.23% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 54.77% | 82.43% | -27.66% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 64.34% | 82.43% | -18.09% |
Dividends
KNSA vs. CRDO - Dividend Comparison
Neither KNSA nor CRDO has paid dividends to shareholders.
Financials
KNSA vs. CRDO - Financials Comparison
This section allows you to compare key financial metrics between Kiniksa Pharmaceuticals, Ltd. and Credo Technology Group Holding Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KNSA vs. CRDO - Profitability Comparison
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 220.03M and revenue of 243.60M. Therefore, the gross margin over that period was 90.3%.
CRDO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Credo Technology Group Holding Ltd reported a gross profit of 298.07M and revenue of 437.00M. Therefore, the gross margin over that period was 68.2%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 27.19M and revenue of 243.60M, resulting in an operating margin of 11.2%.
CRDO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Credo Technology Group Holding Ltd reported an operating income of 155.85M and revenue of 437.00M, resulting in an operating margin of 35.7%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 25.43M and revenue of 243.60M, resulting in a net margin of 10.4%.
CRDO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Credo Technology Group Holding Ltd reported a net income of 169.10M and revenue of 437.00M, resulting in a net margin of 38.7%.
Frequently Asked Questions
KNSA and CRDO have a correlation of -0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRDO has higher volatility (29.83%) compared to KNSA (26.47%). In terms of maximum drawdown, KNSA dropped -83.06% vs CRDO's -62.04%.
KNSA currently has the higher Sharpe Ratio (2.94 vs 0.94), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KNSA and CRDO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer